A living repository that shares our expertise on the microbiome science, investigational fecal microbiota transplantation (FMT), and stool banking.
Fecal Microbiota Transplantation (FMT) has a long history dating back to 300 AD China but has only recently been adopted by Western medical practice. In this paper, we review the basic definition of Fecal Microbiota Transplantation, its development into the standard for care for recurrent C. difficile, and how it may advance medical care for other illnesses.
Stool banking depends on a pool of committed and healthy stool donors. Building a sustainable donor pool can be difficult as less than 3% of prospective donors may pass health screenings, necessitating a large recruitment effort. This paper reviews several considerations for recruiting stool donors including guidance on advertising, designing incentives, and maintaining clear communication with prospective and active donors.
Evaluating the health of stool donors providing Fecal Microbiota Transplantation (FMT) material is a crucial and dynamic aspect of stool banking. Donor selection criteria may vary depending on multiple factors such as geography and patient population, and is continually being updated to reflect the latest understanding of FMT and the microbiome. This paper reviews clinical considerations underlying donor selection using OpenBiome’s screening criteria as an example.
Fecal microbiota transplantation (FMT) preparations comprise minimally processed stool that retain a broad fraction of the stool donor’s complete microbiome. In clinical trials and real-world settings, FMT has been shown to treat approximately 80% of antibiotic-resistant C. difficile infections and is the standard of treatment for recurrent C. difficile. This paper, using OpenBiome as an example, reviews important considerations for manufacturing FMT preparations including safety and operational measures.
Note: Considerations for donor screening are covered separately in a white paper titled “Clinical Considerations for Donor Selection”
Stool banking is a complex, multi-step process that includes screening and monitoring donor health as well as manufacturing fecal microbiota transplantation (FMT) preparations from donated stool. To help ensure that FMT preparations meet the stool bank’s quality and safety standards, a Quality Department reviews all information associated with an FMT preparation and its donor to verify that it is suitable for patient treatment. This paper outlines and discusses basic quality checks that FMT material should pass before it is released for clinical use.
Detection and response to reported safety events is one of a stool bank's most important roles. A robust material tracking and pharmacovigilance program enables timely responses to suspected adverse events including safety measures to mitigate risk to patients receiving FMT at centers being supplied by the stool bank. This paper presents OpenBiome's material tracking and pharmacovigilance program as an example for surveilling patient responses to FMT.
In this paper, we provide an overview on the safety of FMT and important points to consider about the procedure. The perspectives presented here draw from the general safety of FMT sourced from universal stool banks (like OpenBiome) and hospital-based stool banks.
This paper is aimed at physicians and healthcare professionals caring for patients being considered for FMT as well as patients themselves.
Fecal Microbiota Transplantation (FMT) has been shown to treat 80-90% of C. difficile infections not responsive to antibiotic therapy in clinical trials and real-world settings. However, the utility of FMT depends on accurate CDI diagnosis and patient selection. As many as 25% of patients may be incorrectly referred for FMT. This paper covers the considerations when evaluating patients for FMT for the treatment of C. difficile.
Controlled clinical trials and observational studies of Fecal Microbiota Transplantation (FMT) as a treatment for C. difficile infection (CDI) have reported cure rates ranging from 68%-100%. However, such trials and studies have varying definitions of recurrent C. difficile, use different FMT formulations and delivery methods, and treat different patient populations. This paper reviews important points to consider when extrapolating existing efficacy data to the unique situation of an individual patient.